US FDA wants to build a transparent framework that it can consistently apply to decisionmaking about pediatric study waivers for cancer drugs. • Source: Shutterstock
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
